Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: Findings from the LIBERATE study
Journal of the European Academy of Dermatology and Venereology | Dec 15, 2017
Most read this week